The concern of generic competition has repeatedly loomed over copyright’s iconic drug, Viagra, sparking questions about the future of connected drug holdings. While initial periods saw significant gains, the patent end has created the way for less expensive copies, possibly diminishing earnings and presenting a significant danger for stakeholders